Work

The Diagnostic Accuracy of the Metabolic Score for Visceral Fat in Patients with T2DM and Steatotic Liver Disease Associated with Metabolic Dysfunction, Diagnosed by Transient Elastography

Year: 2026
Type: article
Study design: Observational Study
Abstract: Background/Objectives: Excessive accumulation of visceral adipose tissue (VAT) is a significant contributor to the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to evaluate the diagnostic accuracy of the Metabolic Score for Visceral Fat (METS-VF) in identifying patients with MASLD compared with vibration-controlled transient elastography (FibroScan®) in the Slovak (Caucasian) population. Methods: A cross-sectional study of 156 obese/overweight patients, 61 males and 95 females, aged 33–78 years, treated for T2DM or prediabetes and MASLD, on oral antidiabetic medication, was conducted. We performed sex-stratified correlation analyses between METS-VF, the Controlled Attenuation Parameter (CAP) determined by FibroScan®, the Hepatic Steatosis Index (HSI), fat mass and lean mass parameters derived from dual-energy X-ray absorptiometry (DXA), and potential covariates. We fitted multiple linear regression models with CAP as the dependent variable and METS-VF as the independent variable, adjusted for age, sex, and the HOMA index. We then plotted ROC curves using HSI = 36 or a CAP value of 248 dB/m as a steatosis classifier. We then used logistic regression to evaluate the diagnostic value of METS-VF with a CAP of 248 dB/m. Results: We found a significant positive correlation between METS-VF and CAP (r = 0.26, p ≤ 0.001), HSI (r = 0.57, p ≤ 0.001), android fat% (r = 0.29, p ≤ 0.001), and total body fat% (r = 0.18, p ≤ 0.002). The AUC for the CAP in the model calculated from METS-VF and adjusted for the HOMA index, with HSI = 36 as a classifier, was 0.793 (95% CI 0.67–0.91). In the logistic regression analysis 1 SD increase in METS-VF was related to a 1.63-fold greater chance of MASLD in the whole group, (95% CI:1.08–2.46, p ≤ 0.02), AUC 0.661 (CI 0.52–0.79); and a 2.31-fold greater chance of MASLD in females (95% CI:1.20–4.44, p ≤ 0.01), AUC 0.795 (CI 0.66–0.93); in males the OR was statistically not significant (OR = 1.41, 95% CI: 0.76–2.62, p = 0.27), AUC 0.588 (CI 0.38–0.79). Conclusions: Our results demonstrated that METS-VF had a reasonable ability to correctly discriminate patients with MASLD, but with higher performance in the female group only.
Source: Diseases
Language: English
Subfield: Hepatology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,172
OpenAlex ID: W7236570620
FWCI:
Cites: 39
Cited by:
Related to: 10